(HealthDay News) -- New research finds that women with ovarian cancer relapse who start chemotherapy as soon as levels of a biomarker for the cancer rise don't live significantly longer than women who wait until symptoms begin to reappear.
Blood levels of the marker, known as CA125, often precede the reappearance of symptoms in an ovarian cancer relapse, but there has been some debate on the usefulness of monitoring CA125 levels.
"I think the main outcome of this study is going to be to give people confidence that we're not compromising anybody's treatment [if we delay chemotherapy]," said Dr. Andrew Berchuck, director of the division of gynecologic oncology at Duke University Medical Center in Durham, N.C. Read more...
Ayurtox for Body Detoxification
No comments:
Post a Comment